Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04567745 · ClinicalTrials.gov registry record · Phase 1

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers

A Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
80
Enrollment target
1
Study location

NCT04567745: Completed Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Mayo Clinic.

NCT04567745 is a Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment that has completed, run by Mayo Clinic. The registered enrollment target is 80 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04567745, a Phase 1 study of Alzheimer Disease and Mild Cognitive Impairment, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This study aims to provide clinical validation of EyeQuant, a fully automated retinal image analysis system for computation of vascular biomarkers indicative of cognitive disorders, using retinal fundus photographs collected from patients with mild cognitive impairment, Alzheimer's disease, and vascular dementia.

Primary Outcome

The retinal vascular parameters computed using EyeQuant will be compared against the current gold-standard, based on expert annotations

Interventions

  • DIAGNOSTIC_TEST Retinal fundus photography

Study Locations (1)

Arizona

  • Mayo Clinic Arizona - Scottsdale

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2020-09-29
Est. Completion 2021-09-30
Phase Phase 1
Mayo Clinic

2,844 total trials

What the finished NCT04567745 record still lists

NCT04567745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Retinal fundus photography is the first listed.

NCT04567745 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT04567745 about?

NCT04567745 is a clinical study titled "Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers". This study aims to provide clinical validation of EyeQuant, a fully automated retinal image analysis system for computation of vascular biomarkers indicative of cognitive disorders, using retinal fundus photographs collected from patients with mild cognitive impairment, Alzheimer's disease, and vasc...

What is the current status of trial NCT04567745?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2020-09-29. Estimated completion is 2021-09-30.

What conditions does trial NCT04567745 study?

This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia.

What interventions are being tested in trial NCT04567745?

The interventions under investigation include: Retinal fundus photography (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04567745?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04567745 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04567745's enrollment target sits among peer trials

80 168th of 306 higher than 134 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04567745, the US trial registry maintained by the National Library of Medicine. NCT04567745 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.